Advertisement

Topics

[Comment] Bevacizumab in adjuvant treatment of non-small-cell lung cancer

23:08 EST 9 Nov 2017 | The Lancet

Outcomes in early-stage non-small-cell lung cancer (NSCLC) are infamously poor. In the ANITA trial of patients with stage IB–IIIA disease,1 median overall survival for after surgical resection was 43·7 months. Use of adjuvant chemotherapy improved outcome but median overall survival was still only 65·7 months, and meta-analyses2 of NSCLC adjuvant chemotherapy trials suggest a relative survival benefit of just 5% at 5 years.2 When Heather Wakelee and colleagues designed the E1505 trial in 2007, the results of which are reported in The Lancet Oncology, there was a massive unmet need for better therapeutics.

Original Article: [Comment] Bevacizumab in adjuvant treatment of non-small-cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "[Comment] Bevacizumab in adjuvant treatment of non-small-cell lung cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...